FLUTCORE

Development of a universal influenza vaccine based on tandem core technology

 Coordinatore UNIVERSITY COLLEGE LONDON 

 Organization address address: GOWER STREET
city: LONDON
postcode: WC1E 6BT

contact info
Titolo: Ms.
Nome: Amelie
Cognome: Guisseau
Email: send email
Telefono: +44 20 76798329

 Nazionalità Coordinatore United Kingdom [UK]
 Totale costo 5˙063˙520 €
 EC contributo 3˙872˙919 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2013-INNOVATION-1
 Funding Scheme CP-FP
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-09-01   -   2017-03-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSITY COLLEGE LONDON

 Organization address address: GOWER STREET
city: LONDON
postcode: WC1E 6BT

contact info
Titolo: Ms.
Nome: Amelie
Cognome: Guisseau
Email: send email
Telefono: +44 20 76798329

UK (LONDON) coordinator 838˙259.00
2    IQUR LIMITED

 Organization address address: ROYAL COLLEGE STREET 2 LONDON
city: LONDON
postcode: NW1 0NH

contact info
Titolo: Dr.
Nome: Mike
Cognome: Whelan
Email: send email
Telefono: +44 2076368219

UK (LONDON) participant 966˙822.00
3    3P BIOPHARMACEUTICALS SL

 Organization address address: CALLE MOCHOLI 2 POLIGONO MOCHOLI
city: NOAIN NAVARRA
postcode: 31110

contact info
Titolo: Ms.
Nome: Barbara
Cognome: Fernandez De Manzanos
Email: send email
Telefono: +34 948346480
Fax: +34 948346702

ES (NOAIN NAVARRA) participant 754˙961.00
4    Luxembourg Institute of Health

 Organization address address: Val Fleuri 84
city: LUXEMBOURG
postcode: 1526

contact info
Titolo: Mr.
Nome: Thomas
Cognome: Lentz
Email: send email
Telefono: +352 269 70821
Fax: +352 269 719

LU (LUXEMBOURG) participant 664˙443.00
5    LATVIJAS BIOMEDICINAS PETIJUMU UN STUDIJU CENTRS

 Organization address address: RATSUPITES IELA 1
city: RIGA
postcode: 1067

contact info
Nome: Liga
Cognome: Vonda
Email: send email
Telefono: +371 67808206
Fax: +371 67442407

LV (RIGA) participant 300˙030.00
6    UNIVERSITY OF LEEDS

 Organization address address: WOODHOUSE LANE
city: LEEDS
postcode: LS2 9JT

contact info
Titolo: Mr.
Nome: Martin
Cognome: Hamilton
Email: send email
Telefono: +44 113 343 4090
Fax: +44 113 343 0949

UK (LEEDS) participant 266˙984.00
7    INSTITUT CATALA DE LA SALUT

 Organization address address: GRAN VIA DE LES CORTS CATALANES 587
city: BARCELONA
postcode: 8007

contact info
Titolo: Dr.
Nome: Joan X.
Cognome: Comella
Email: send email
Telefono: 34934894013
Fax: 34934894102

ES (BARCELONA) participant 81˙420.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

vaccines    universal    clinical    vlp    influenza    core    then    virus    antigens    once    flutcore    immune    vaccine    iav    manufacture    invariant    examine    tandem    immunogenicity   

 Obiettivo del progetto (Objective)

'FLUTCORE will develop a novel universal influenza A virus (IAV) vaccine based on the tandem core vaccine platform. Recent influenza pandemics have emphasized the urgent need for better vaccines that are reactive with multiple IAV subtypes and that are no longer dependent on intimate knowledge of the prevalent virus. We propose to replace the existing seasonal IAV vaccine with a virus like particle (VLP) carrying several invariant “universal” influenza antigens. Previous attempts to use these targets have failed due to the poor antigen expression and immunogenicity. The highly immunogenic tandem core system overcomes this limitation. Specifically, we propose to develop a VLP carrying two or more invariant influenza antigens, express these in yeast and then examine immunogenicity in mice. The vaccine will be further tested in the rigorous ferret system before being scaled up for manufacture. An optimal clone will then be transferred to an accredited contract manufacturer for production. A phase I clinical trial will be carried out once pre-clinical toxicology has been successfully completed. Our consortium will examine the immune responses in both animals and humans thoroughly to ensure that the vaccine candidate chosen can produce a protective IAV immune response in all individuals. To achieve these objectives, our proposal builds upon the complementary expertise of seven high-performing partners representing four European countries, with world leadership in HBV core biology, immunological analysis, commercial manufacture and influenza clinical trials, making our consortium ideally positioned to develop the vaccine and to take it from bench to bedside. The leading role of SMEs in the consortium will ensure that the technology developed by FLUTCORE will generate highly marketable products, offering both improved patient protection and long-term cost savings for health care in Europe once annual influenza vaccines are replaced.'

Altri progetti dello stesso programma (FP7-HEALTH)

TACTIC (2013)

Targeted Action for Curing Trauma Induced Coagulopathy

Read More  

COPACETIC (2008)

"COPD Pathology: Addressing Critical gaps, Early Treatment and Innovative Concepts"

Read More  

ISSC (2010)

An integrated surveillance system for infectious disease in rural China: generating evidence for early detection of disease epidemics in resource-poor settings

Read More